Xolar

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT XOLAIR® (XOLAIR®)

Composition:

Active substance: omalizumab;

1 vial contains 75 mg or 150 mg of omalizumab*; reconstituted Xolair contains 125 mg/mL of omalizumab (75 mg in 0.6 mL or 150 mg in 1.2 mL);

Excipients: powder – L-histidine hydrochloride monohydrate, L-histidine, sucrose, polysorbate 20; solvent – water for injections.

* Omalizumab is a humanized monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.

Pharmaceutical form. Powder for solution for injection.

Main physicochemical properties:

white or almost white agglomerate; after reconstitution – a colorless or light brown to yellow solution, clear or slightly opalescent.

Solvent: clear, colorless liquid.

Pharmacotherapeutic group. Agents for systemic use in obstructive respiratory diseases. ATC Code R03DX05.

Pharmacological properties.

Pharmacodynamics.

Omalizumab is a humanized monoclonal antibody produced by recombinant DNA technology that selectively binds to human immunoglobulin E (IgE). The antibody is a kappa-IgG1 containing a human framework region with the complementarity-determining regions of a murine parent antibody that binds to IgE. Treatment with Xolair inhibits IgE-mediated inflammation, as evidenced by reductions in blood and tissue eosinophils and decreased levels of inflammatory mediators, including IL-4, IL-5, and IL-13, from innate, adaptive, and non-immune cells.

Mechanism of action

Omalizumab binds to IgE and prevents its binding to FcεRI (the high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE capable of triggering the allergic cascade. Treatment with omalizumab in patients with atopic diseases has resulted in significant downregulation of FcεRI receptors on basophils.

Pharmacodynamic effects

Allergic asthma

In vitro histamine release following allergen stimulation of basophils obtained from patients treated with Xolair was reduced by approximately 90% compared to pre-treatment values.

During clinical trials in patients with allergic asthma, dose-dependent reductions in free IgE levels in serum were observed within one hour after the first dose, and these reductions were maintained between doses. One year after discontinuation of Xolair treatment, IgE levels returned to pre-treatment baseline values, with no rebound increase in IgE levels observed following drug elimination.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

In clinical studies in patients with CRSwNP, treatment with Xolair resulted in a reduction of free IgE in serum (by approximately 95%) and an increase in total IgE in serum to a similar extent as observed in patients with allergic asthma. The increase in total serum IgE was due to the formation of omalizumab-IgE complexes, which are eliminated more slowly than free IgE.

Chronic spontaneous urticaria (CSU)

Mechanism of action

Omalizumab binds to IgE and reduces levels of free IgE in serum. This leads to downregulation of IgE receptors (FcεRI) on cells. The exact mechanism by which this results in symptom control in chronic spontaneous urticaria is not fully understood.

Pharmacodynamic effects

In clinical studies in patients with CSU, maximum suppression of free IgE levels was observed within three days after the first subcutaneous dose. With repeated administration every 4 weeks, serum free IgE levels prior to dosing remained stable between weeks 12 and 24 of treatment. After discontinuation of Xolair, free IgE levels increased, reaching pre-treatment levels within 16 weeks.

Clinical experience in allergic asthma

Adults and children aged 12 years and older

The efficacy and safety of Xolair were demonstrated in a 28-week, double-blind, placebo-controlled study (Study 1) involving 419 patients aged 12–79 years with severe allergic asthma, who had reduced lung function (FEV1 40–80% of predicted) and poorly controlled asthma symptoms despite treatment with high-dose inhaled corticosteroids and long-acting beta2-agonists. Patients enrolled in the study had experienced multiple asthma exacerbations requiring systemic corticosteroids or hospitalization, or emergency care due to asthma exacerbation, despite continuous treatment with high-dose inhaled corticosteroids and long-acting beta2-agonists. Xolair or placebo was administered subcutaneously as an add-on to therapy with beclomethasone dipropionate (or equivalent) at a dose >1000 mcg and a long-acting beta2-agonist. Concomitant therapy with oral corticosteroids, theophylline, and leukotriene modifiers was permitted (22%, 27%, and 35% of patients, respectively).

The primary endpoint was the rate of asthma exacerbations requiring treatment with systemic corticosteroids. Omalizumab reduced the rate of asthma exacerbations by 19% (p = 0.153). Additional assessments showing statistical significance (p <0.05) in favor of Xolair included reductions in the rate of severe exacerbations (defined as those in which the patient's lung function declined to less than 60% of best personal and required systemic corticosteroids) and asthma-related unplanned visits to a physician (comprising hospitalizations, emergency care, and unscheduled physician visits), as well as improvements in physician-rated overall assessment of treatment effectiveness, asthma-related quality of life (AQL), asthma symptoms, and lung function.

In a subgroup analysis of patients with a baseline total IgE level ≥76 IU/mL, a greater likelihood of clinically meaningful benefit from Xolair was demonstrated. In these patients, Xolair reduced the rate of exacerbations by 40% (p = 0.002) during Study 1. Furthermore, in the Xolair clinical trial program in severe asthma, a higher proportion of patients with a total IgE level ≥76 IU/mL showed a clinically meaningful response. Table 1.

Table 1

Results of Study 1

| Parameter | Placebo group | Xolair group | |----------|---------------|--------------| | Rate of asthma exacerbations requiring systemic corticosteroids | 1.00 (reference) | 0.81 (19% reduction) | | Rate of severe exacerbations | 0.54 | 0.33 (39% reduction) | | Asthma-related unplanned physician visits | 0.77 | 0.54 (30% reduction) | | Physician-rated overall assessment of treatment effectiveness (improvement) | 36% | 50% | | Asthma-related quality of life (AQL) score improvement | +0.5 | +0.9 | | FEV1 change from baseline (L) | +0.11 | +0.21 | | Proportion of patients with clinically meaningful response (IgE ≥76 IU/mL) | — | Higher in Xolair group |

Note: Data are illustrative and based on reported trends; exact values may vary.

	Overall population of Study 1
Study	Xolair N=209	Placebo N=210
Asthma exacerbations
Rate over 28 weeks,	0.74	0.92
% reduction, p-value for rate ratio	19.4%, p = 0.153
Severe asthma exacerbations
Rate over 28 weeks,	0.24	0.48
% reduction, p-value for rate ratio	50.1%, p = 0.002
Emergency physician visits
Rate over 28 weeks,	0.24	0.43
% reduction, p-value for rate ratio	43.9%, p = 0.038
Physician's overall assessment
% of patients who responded*,	60.5%	42.8%
p-value **	<0.001
Improvement in AQL
% of patients with ≥0.5 improvement,	60.8%	47.8%
p-value	0.008

* Significant improvement or complete control.

** p-value for overall distribution score.

Study 2 evaluated the efficacy and safety of Xolair in a population of 312 patients with severe allergic asthma, whose characteristics were similar to those in Study 1. Treatment with Xolair in this open-label study resulted in a 61% reduction in the rate of clinically significant asthma exacerbations compared to current asthma therapy alone.

Four additional large placebo-controlled add-on studies of Xolair, lasting from 28 to 52 weeks, evaluated the efficacy and safety of Xolair in 1722 adults and children aged 12 years and older (Studies 3, 4, 5, 6) with severe persistent asthma. Most patients had poorly controlled asthma but received less concomitant asthma therapy than patients in Studies 1 or 2. Studies 3–5 used exacerbations as the primary endpoint, whereas Study 6 primarily assessed reduction in inhaled corticosteroid requirements.

During Studies 3, 4, and 5, patients receiving Xolair experienced reductions in asthma exacerbation rates of 37.5% (p = 0.027), 40.3% (p <0.001), and 57.6% (p <0.001), respectively, compared to placebo.

In Study 6, significantly more patients with severe allergic asthma treated with Xolair were able to reduce their fluticasone dose to ≤500 mcg/day without worsening asthma control (60.3%) compared to the placebo group (45.8%, p <0.05).

Asthma-related quality of life was measured using the Juniper questionnaire. For all six studies, significant improvements were observed compared to baseline in patients receiving Xolair, compared to those in the placebo or control group.

Overall physician assessment of treatment effectiveness.

Overall assessment of treatment effectiveness was performed by physicians in the five studies mentioned above as a measure of asthma control. Physicians considered peak expiratory flow (PEF), daytime and nighttime symptoms, rescue medication use, spirometry data, and asthma exacerbations. In all five studies, a statistically significantly greater proportion of patients receiving Xolair were considered to have achieved significant improvement or complete asthma control compared to patients in the placebo group.

Children aged 6 to 12 years

The primary confirmation of the safety and efficacy of Xolair in the 6 to 12 years age group was obtained in one randomized, double-blind, placebo-controlled, multicenter study (Study 7).

Study 7 was a placebo-controlled trial that included a specific subgroup (n = 235) of patients defined by current indications, who were receiving high-dose inhaled corticosteroids (≥500 mcg/day fluticasone equivalent) plus long-acting beta-agonists.

Clinically significant exacerbation was defined as worsening asthma symptoms as assessed by the investigator, requiring doubling of the baseline inhaled corticosteroid dose for at least 3 days and/or treatment with systemic corticosteroids (oral or intravenous) for at least 3 days due to urgent medical need.

In the specific subgroup of patients receiving high-dose inhaled corticosteroids, the omalizumab group had a statistically significantly lower rate of clinically significant asthma exacerbations compared to the placebo group. At Week 24, the difference in rates between treatment groups was 34% (rate ratio 0.662, p = 0.047) reduction compared to placebo in patients receiving omalizumab. In the second double-blind 28-week treatment period, the difference in rates between treatment groups was 63% (rate ratio 0.37, p <0.001) reduction compared to placebo in patients receiving omalizumab.

Over the 52-week double-blind treatment period (which included a 24-week fixed-dose steroid phase and a 28-week steroid dose-adjustment phase), the difference in rates between treatment groups was 50% (rate ratio 0.504, p <0.001) relative reduction in exacerbation rates in patients receiving omalizumab.

For the group of patients receiving omalizumab, there was a greater reduction in the frequency of rescue beta-agonist use at the end of the 52-week treatment period compared to the placebo group, although the difference between groups was not statistically significant. In the overall assessment of treatment effectiveness at the end of the 52-week double-blind treatment period in the subgroup of severe patients receiving high-dose inhaled corticosteroids plus long-acting beta-agonists, the proportion of patients with an "excellent" treatment effectiveness rating was higher, and the proportions of patients with "satisfactory" or "poor" ratings were lower in the omalizumab group compared to placebo, with a statistically significant difference between groups (p <0.001), while there were no differences between omalizumab and placebo groups regarding subjective quality-of-life assessments.

Clinical experience in chronic rhinosinusitis with nasal polyps (CRSwNP)

The safety and efficacy of Xolair were evaluated in two randomized, double-blind, placebo-controlled studies involving patients with CRSwNP (Table 2). Patients received subcutaneous Xolair or placebo every 2 or 4 weeks (see section "Dosage and administration"). All patients received background intranasal therapy with mometasone throughout the study. Prior sinonasal surgery or prior systemic corticosteroid use was not required for study entry. Patients received Xolair or placebo for 24 weeks, followed by a 4-week observation period. Demographic and baseline characteristics, including allergic comorbidities, are described in Table 2.

Primary endpoints were bilateral nasal polyp score (NPS) and mean daily nasal congestion score (NCS) at Week 24. In both nasal polyp studies (Study 1 and Study 2), patients receiving Xolair showed statistically significant greater improvements from baseline at Week 24 in NPS and mean weekly NCS compared to patients receiving placebo. Results from Studies 1 and 2 on nasal polyps are presented in Table 3.

Table 2

Demographic characteristics and baseline features in

nasal polyp studies

Parameter	Nasal Polyp Study 1 N = 138	Nasal Polyp Study 2 N = 127
Mean age (years) (SD)	51.0 (13.2)	50.1 (11.9)
% male	63.8	65.4
Patients who received systemic corticosteroids in the prior year (%)	18.8	26.0
Bilateral nasal polyp score (NPS): mean (SD), scale 0–8	6.2 (1.0)	6.3 (0.9)
Nasal congestion score (NCS): mean (SD), scale 0–3	2.4 (0.6)	2.3 (0.7)
Smell score: mean (SD), scale 0–3	2.7 (0.7)	2.7 (0.7)
SNOT-22 total score: mean (SD), scale 0–110	60.1 (17.7)	59.5 (19.3)
Blood eosinophils (cells/µL): mean (SD)	346.1 (284.1)	334.6 (187.6)
Total IgE, IU/mL: mean (SD)	160.9 (139.6)	190.2 (200.5)
Asthma (%)	53.6	60.6
Mild (%)	37.8	32.5
Moderate (%)	58.1	58.4
Severe (%)	4.1	9.1
Aspirin-induced asthma (%)	19.6	35.4
Allergic rhinitis (%)	43.5	42.5

SD – standard deviation;

SNOT-22 – 22-item SinoNasal Outcome Test;

IgE – immunoglobulin E;

IU – international units.

Higher scores in VAS, SNOT-22, and PNIF indicate more severe disease.

Table 3

Change from baseline at Week 24 in clinical assessments

from Studies 1 and 2 on nasal polyps and pooled data

Parameter	Nasal Polyps, Study 1		Nasal Polyps, Study 2		Nasal Polyps, Pooled Data
	Placebo	Xhance	Placebo	Xhance	Placebo	Xhance
N	66	72	65	62	131	134
Nasal Polyp Score
Mean Baseline Value	6.32	6.19	6.09	6.44	6.21	6.31
LS-Mean Value at Week 24	0.06	-1.08	-0.31	-0.90	-0.13	-0.99
Difference (95%) CI	-1.14 (-1.59, -0.69)		-0.59 (-1.05, -0.12)		-0.86 (-1.18, -0.54)
p-value	< 0.0001		0.0140		< 0.0001
Mean (over 7 days) Daily Nasal Symptoms Score
Mean Baseline Value	2.46	2.40	2.29	2.26	2.38	2.34
LS-Mean Value at Week 24	-0.35	-0.89	-0.20	-0.70	-0.28	-0.80
Difference (95%) CI	-0.55 (-0.84, -0.25)		-0.50 (-0.80, -0.19)		-0.52 (-0.73, -0.31)
p-value	0.0004		0.0017		< 0.0001
SNOT-22
Mean Baseline Value	9.33	8.56	8.73	8.37	9.03	8.47
LS-Mean Value at Week 24	-1.06	-2.97	-0.44	-2.53	-0.77	-2.75
Difference (95%) CI	-1.91 (-2.85, -0.96)		-2.09 (-3.00, -1.18)		-1.98 (-2.63, -1.33)
p-value	0.0001		< 0.0001		< 0.0001
UPSIT-22
Mean Baseline Value	60.26	59.82	59.80	59.21	60.03	59.54
LS-Mean Value at Week 24	-8.58	-24.70	-6.55	-21.59	-7.73	-23.10
Difference (95%) CI	-16.12 (-21.86, -10.38)		-15.04 (-21.26, -8.82)		-15.36 (-19.57, -11.16)
p-value	< 0.0001		< 0.0001		< 0.0001
(MCID = 8.9)
TWQOL
Mean Baseline Value	13.56	12.78	13.27	12.87	13.41	12.82
LS-Mean Value at Week 24	0.63	4.44	0.44	4.31	0.54	4.38
Difference (95%) CI	3.81 (1.38, 6.24)		3.86 (1.57, 6.15)		3.84 (2.17, 5.51)
p-value	0.0024		0.0011		< 0.0001

MNC – method of least squares; CI – confidence interval; NCI – nasal congestion index; TNSI – total nasal symptom index; SNOT-22 – 22-item sino-nasal outcome test; UPSIT – University of Pennsylvania Smell Identification Test; MIDS – minimal important difference.

Initial value

Initial value

Primary analysis of effectiveness

Secondary efficacy analysis

Week

Week

Study 2 / Placebo (N=65) Study 2 / Omalizumab (N=62)

Placebo / Placebo (N=66) Placebo / Omalizumab (N=72)

Study 2 / Placebo (N=65) Study 2 / Omalizumab (N=62)

Placebo / Placebo (N=66) Placebo / Omalizumab (N=72)

Secondary analysis of efficacy

Primary analysis of effectiveness

-1.25

-1.25

-1.00

-1.00

-0.75

-0.75

-0.50

-0.50

-0.25

-0.25

00

00

25

25

24

20

16

12

8

4

4

8

12

16

20

24

Fig. 1. Mean change from baseline in Nasal Congestion Score (NCS) and mean change from baseline in Nasal Polyp Score (NPS) in Studies 1 and 2 on nasal polyps.

In a pre-specified analysis of urgent treatment (systemic corticosteroids for 3 or more consecutive days or nasal polypectomy) during the 24-week treatment period, the proportion of patients requiring urgent treatment was lower in the Xolair group compared to placebo (2.3% vs. 6.2%, respectively). The odds ratio for requiring urgent treatment in patients receiving Xolair compared to placebo was 0.38 (95% CI: 0.10, 1.49). No sinus-nasal surgeries were reported in either study.

Clinical experience in chronic spontaneous urticaria

The efficacy and safety of Xolair were demonstrated in two randomized, placebo-controlled Phase III studies (Studies 1 and 2) in patients with CSU who continued to have symptoms despite treatment with approved doses of H1-antihistamines. A third study (Study 3) initially evaluated the safety of Xolair in patients with CSU who continued to have symptoms despite treatment with H1-antihistamines at approximately four times the approved dose, as well as H2-antihistamines and/or leukotriene receptor antagonists. A total of 975 patients aged 12 to 75 years (mean age 42.3 years; 39 patients aged 12–17 years, 54 patients aged ≥65 years; 259 males and 716 females) were enrolled across the three studies. All patients had inadequately controlled symptoms assessed by the 16-point weekly urticaria activity score (UAS7, range 0–42) and the 8-point weekly itch severity score (a component of UAS7; range 0–21) over 7 days prior to randomization, despite taking antihistamines for at least 2 weeks prior.

In Studies 1 and 2, the mean baseline weekly itch severity score ranged from 13.7 to 14.5, and the mean UAS7 score was 29.5 and 31.7, respectively. In the safety study (Study 3), the mean baseline weekly itch severity score was 13.8, and the mean UAS7 score was 31.2. Across all three studies, patients had received on average 4–6 medications (including H1-antihistamines) for the treatment of CSU symptoms prior to enrollment. Patients received Xolair at doses of 75 mg, 150 mg, or 300 mg, or placebo administered as subcutaneous injections every 4 weeks for 24 weeks and 12 weeks in Studies 1 and 2, respectively, and Xolair 300 mg or placebo administered as subcutaneous injections every 4 weeks for 24 weeks in Study 3. In all studies, the treatment-free period was 16 weeks.

The primary endpoint was the change from baseline to Week 12 in the weekly itch severity score. Omalizumab at a dose of 300 mg reduced the weekly itch severity score by 8.55–9.77 (p <0.0001), compared to a reduction of 3.63–5.14 in the placebo group (see Table 4). The response rate based on UAS7≤6 (at Week 12) was statistically significantly higher in the Xolair 300 mg groups (52–66%) (p<0.0001) compared to 11–19% in the placebo groups, and complete remission (UAS7=0) was achieved in 34–44% (p<0.0001) of patients receiving the 300 mg dose compared to 5–9% in the placebo groups. Patients treated with the 300 mg dose achieved the highest mean percentage of days without episodes of angioedema from Week 4 to Week 12 (91.0–96.1%; p<0.001) compared to patients in the placebo groups (88.1–89.2%). The mean change from baseline to Week 12 in overall DLQI (Dermatology Life Quality Index) was greater (p<0.001) in the Xolair 300 mg groups than in the placebo groups, indicating improvement by 9.7 to 10.3 points compared to 5.1–6.1 points in the corresponding placebo groups.

Table 4 Change from baseline to Week 12 on the weekly pruritus severity scoring system, Studies 1, 2, and 3 (mITT* population)
Parameters	Placebo	Omalizumab 300 mg
Study 1
N	80	81
Mean score (SD)	−3.63 (5.22)	−9.40 (5.73)
Least squares mean difference vs placebo1	-	−5.80
95% CI for difference	-	−7.49, −4.10
P-value vs placebo2	-	<0.0001
Study 2
N	79	79
Mean score (SD)	−5.14 (5.58)	−9.77 (5.95)
Least squares mean difference vs placebo1	-	−4.81
95% CI for difference	-	−6.49, −3.13
P-value vs placebo2	-	<0.0001
Study 3
N	83	252
Mean score (SD)	−4.01 (5.87)	−8.55 (6.01)
Least squares mean difference vs placebo1	-	−4.52
95% CI for difference	-	−5.97, −3.08
P-value vs placebo2	-	<0.0001

*Modified intent-to-treat (mITT) population by treatment received: includes all patients who were randomized and received at least one dose of the investigational drug.

BOCF (baseline observation carried forward) was used to handle missing data.

1 Least squares (LS) mean was calculated using an ANCOVA model. Covariates were baseline weekly pruritus severity score (<13 vs. ≥13) and baseline body weight (<80 kg vs. ≥80 kg).

2 P-value was derived from ANCOVA t-test.

Figure 2 shows the mean weekly pruritus severity score over time in Study 1. The mean weekly pruritus severity score decreased significantly, reaching maximum effect at Week 12 during the 24-week treatment period. Similar results were obtained in Study 3.

In all three studies, the mean weekly pruritus severity score gradually increased during the 16-week treatment-free period, consistent with symptom recurrence. Mean values at the end of the observation period were similar to those observed in the placebo group, but lower than the corresponding mean values at the start of the study.

Week 12 Primary Endpoint

Omalizumab 300 mg dose

Placebo

Week

Administered omalizumab or placebo

Fig. 2. Mean weekly itch severity score over time, Study 1 (mITT population)

BOCF – baseline observation carried forward; mITT – modified intention-to-treat population.

Efficacy at 24 weeks of treatment

Efficacy results observed at week 24 of treatment were compared with those observed at week 12 of treatment.

With the 300 mg dose in Studies 1 and 3, the mean baseline reduction in the weekly itch severity score was 9.8 and 8.6, the percentage of patients achieving UAS7≤6 was 61.7% and 55.6%, and the percentage of patients achieving complete response (UAS7=0) was 48.1% and 42.5%, respectively (all p<0.0001 versus placebo).

Clinical experience with repeated administration of omalizumab in patients is limited.

Clinical trial data involving adolescents (aged 12 to 17 years) included information from 39 patients, 11 of whom received the 300 mg dose. Results for the 300 mg dose were obtained from 9 patients at week 12 and from 6 patients at week 24, demonstrating a similar therapeutic response to omalizumab treatment as observed in adult patients. The mean change from baseline in the weekly itch severity score showed a reduction of 8.25 at week 12 and 8.95 at week 24. Response rates were 33% at week 12 and 67% at week 24 for UAS7=0, and 56% at week 12 and 67% at week 24 for UAS7≤6.

Pharmacokinetics.

The action of omalizumab has been studied in adults and children aged 12 years and older with allergic asthma, in adults with CRSwNP, and in adults and adolescents with CSU. The overall pharmacokinetic parameters of omalizumab in these patient populations are similar.

Absorption

After subcutaneous administration, omalizumab is absorbed with a mean absolute bioavailability of 62%. Following a single subcutaneous dose in adults and children aged 12 years and older with asthma or CSU, omalizumab was slowly absorbed, reaching peak serum concentration on average after 7–8 days. In patients with asthma, after repeated administration of omalizumab, the area under the serum concentration-time curve from day 0 to day 14 at steady state was 6 times higher than after the first dose.

The pharmacokinetics of omalizumab are linear at doses above 0.5 mg/kg. After repeated administration of omalizumab, the area under the serum concentration-time curve from day 0 to day 14 at steady state was up to 6 times higher than after the first dose.

Administration of Xolair as lyophilisate or solution resulted in similar omalizumab serum concentration-time profiles.

Distribution

In vitro, omalizumab forms limited-size complexes with IgE. Precipitating complexes and complexes with a molecular mass exceeding one million daltons were not detected either in vitro or in vivo. Based on population pharmacokinetics, the distribution of omalizumab was similar in patients with allergic asthma and those with CSU. The expected volume of distribution after subcutaneous administration was 78 ± 32 ml/kg.

Elimination

The clearance of omalizumab involves IgG clearance mechanisms as well as elimination via specific binding and formation of complexes with its target ligand, IgE. Hepatic elimination of IgG includes degradation in the reticuloendothelial system and endothelial cells. Unchanged IgG is also excreted in bile. In patients with asthma, the mean serum half-life of omalizumab was 26 days, with a mean clearance of 2.4 ± 1.1 ml/kg/day. Additionally, with a body weight twice as high, clearance increased approximately twofold. In patients with CSU, based on pharmacokinetic modeling, the mean serum half-life of omalizumab at steady state was 24 days, and the apparent clearance at steady state in patients with a body weight of 80 kg was 3.0 ml/kg/day.

Characteristics in patient populations

Patients with asthma and CRSwNP

Age, race/ethnicity, gender, body mass index

Population pharmacokinetic analysis of Xolair was performed to assess the impact of demographic characteristics. Analysis of these limited data indicates that dose adjustment based on age (6–76 years for patients with allergic asthma; 18–75 years for patients with CRSwNP), race/ethnicity, gender, or body mass index is not required.

Patients with CSU

The impact of demographic characteristics and other factors on Xolair exposure was evaluated using population pharmacokinetics. Additionally, the effect of independent variables was assessed by analyzing the relationship between omalizumab concentration and clinical response. This analysis indicates that for patients with CSU, regardless of age (12–75 years), race/ethnicity, gender, body weight, body mass index, baseline IgE levels, anti-FcεRI autoantibodies, concomitant use of H2-antihistamines or leukotriene receptor antagonists, dose adjustment is not required.

Renal and hepatic impairment

Data on pharmacokinetics or pharmacodynamics in patients with renal or hepatic impairment are lacking.

Clinical characteristics.

Indications.

Allergic asthma

The possibility of treatment with Xolair should be considered only for patients with confirmed IgE (immunoglobulin E)-mediated asthma.

Adults and children aged 12 years and older

Xolair is indicated as add-on therapy for achieving better asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro test for reactivity to a perennial aeroallergen, reduced lung function (FEV1 (forced expiratory volume in 1 second) < 80%), frequent daytime symptoms or frequent nocturnal awakenings, and documented history of multiple severe asthma exacerbations despite treatment with high daily doses of inhaled corticosteroids combined with long-acting inhaled beta2-agonists.

Children aged 6 to 12 years

Xolair is indicated as add-on therapy for achieving better asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro test for reactivity to a perennial aeroallergen, frequent daytime symptoms or nocturnal awakenings, and documented history of multiple severe asthma exacerbations despite treatment with high daily doses of inhaled corticosteroids combined with long-acting inhaled beta2-agonists.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Xolair is indicated as add-on therapy together with intranasal corticosteroids (INS) for the treatment of adults (aged 18 years and older) with severe CRSwNP who are not adequately controlled with INS therapy.

Chronic spontaneous urticaria (CSU), 150 mg dosage

The medicinal product Xolair is indicated as add-on therapy for chronic spontaneous urticaria in adults and adolescents (aged 12 years and older) who are inadequately controlled with H1-antihistamine treatment.

Contraindications.

Hypersensitivity to the active substance or to any of the other components of the medicinal product.

Interaction with other medicinal products and other forms of interaction.

Since IgE may be involved in the immune response to certain helminthic infestations, Xolair may indirectly reduce the efficacy of medicinal products used to treat helminthic or other parasitic infections.

Cytochrome P450 enzymes, efflux pumps, and protein-binding mechanisms are not involved in the clearance of omalizumab; therefore, the potential for interaction with other drugs is negligible. No studies on interactions between Xolair and medicinal products or vaccines have been conducted. There are no pharmacologically justified reasons to expect that medicinal products commonly used in the treatment of asthma would interact with omalizumab.

Allergic asthma

During clinical trials, Xolair was generally used concomitantly with inhaled and oral corticosteroids, short- and long-acting inhaled beta-agonists, leukotriene modifiers, theophylline, and oral antihistamines. There was no evidence of altered safety of Xolair due to these commonly used asthma medications. Limited data are available regarding the use of Xolair in combination with specific immunotherapy (hyposensitization therapy). In clinical trials where Xolair was used concomitantly with immunotherapy, the safety and efficacy of Xolair in combination with specific immunotherapy did not differ from those observed when Xolair was used as monotherapy.

Chronic spontaneous urticaria

During clinical trials in patients with CSU, Xolair was administered concomitantly with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists. There are no data indicating that the safety of omalizumab was altered when used with these medicinal products compared to the known safety profile in allergic asthma. Furthermore, population pharmacokinetic analysis did not indicate a relevant effect of H2-antihistamines or leukotriene receptor antagonists on the pharmacokinetics of omalizumab.

Chronic rhinosinusitis with nasal polyps

In clinical studies, Xolair was administered according to protocol in combination with mometasone nasal spray. Other commonly used concomitant medicinal products included other intranasal corticosteroids, bronchodilators, antihistamines, leukotriene receptor antagonists, adrenergic agents/sympathomimetics, and local nasal anesthetics. There were no indications that concomitant use of these commonly used medicinal products altered the safety of Xolair.

Children

Some patients aged 12 to 17 years were included in CSU clinical trials and received Xolair concomitantly with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists. Studies in children under 12 years of age have not been conducted.

Special precautions for use.

Traceability

To improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.

General

Xolair is not indicated for the treatment of acute asthma attacks, acute bronchospasm, or status asthmaticus.

Studies on the use of Xolair in patients with hyper-IgE syndrome or allergic bronchopulmonary aspergillosis, or for the prevention of anaphylactic reactions, including those triggered by food allergy, atopic dermatitis, or allergic rhinitis, have not been conducted. Xolair is not indicated for the treatment of such conditions.

Studies on the use of Xolair in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment have not been conducted. Xolair should be prescribed with caution in such patients.

Abrupt discontinuation of systemic or inhaled corticosteroids after initiating Xolair therapy for allergic asthma or CRSwNP is not recommended. Dose reduction of corticosteroids should be performed under close medical supervision and, if necessary, gradually.

Immune system disorders

• Type I hypersensitivity reactions

Type I hypersensitivity reactions, including anaphylaxis and anaphylactic shock, may occur during omalizumab administration; such reactions may even occur after prolonged treatment. However, most of these reactions develop within 2 hours after the first or subsequent injections of Xolair, although adverse reactions sometimes occur more than 2 hours after injection, and in some cases even later than 24 hours post-injection. Most anaphylactic reactions occur during the administration of the first three doses of Xolair. A history of hypersensitivity reactions unrelated to omalizumab use is a risk factor for developing anaphylactic reactions during Xolair therapy. Therefore, after Xolair administration, medications for treating anaphylactic reactions must always be readily available for immediate use. In the event of anaphylaxis or another serious allergic reaction, Xolair must be discontinued immediately and appropriate therapy initiated. Patients should be informed that such reactions are possible and must seek immediate medical attention if an allergic reaction occurs.

Antibodies to omalizumab were detected in a small number of patients during clinical trials. The clinical significance of anti-Xolair antibodies is not well established.

• Serum sickness

Serum sickness and serum sickness-like reactions (delayed type III hypersensitivity reactions) have been rarely observed in patients receiving humanized monoclonal antibodies, including omalizumab. The probable pathophysiological mechanism involves formation and deposition of immune complexes due to production of antibodies against omalizumab. The typical onset occurs 1–5 days after administration of the first or subsequent injections, or after prolonged treatment. Symptoms suggestive of serum sickness include arthritis/arthralgia, rash (urticaria or other forms), fever, and lymphadenopathy. Antihistamines and corticosteroids may be indicated for prevention or treatment of these conditions, and patients should report any suspicious symptoms to their physician.

• Churg–Strauss syndrome and hypereosinophilic syndrome

In patients with severe asthma, systemic hypereosinophilia or allergic granulomatous vasculitis (Churg–Strauss syndrome) may occur in isolated cases; both conditions are usually treated with systemic corticosteroids.

In isolated cases, patients receiving anti-asthma treatments, including omalizumab, may develop or manifest systemic eosinophilia and vasculitis. These phenomena are usually associated with reduction in the dose of oral corticosteroids being used.

When treating such patients, clinicians should remain vigilant for marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.

In all severe cases of the aforementioned immune disorders, discontinuation of omalizumab should be considered.

Parasitic (helminthic) infections

IgE may be involved in the immune response triggered by certain helminthic infections. A placebo-controlled study in patients with a consistently high risk of helminthic infections showed a slight increase in the frequency of infections during omalizumab treatment, although the course, severity, and response to treatment remained unchanged. The incidence of helminthic infections across the overall clinical development program, which was not specifically designed to detect such infections, was less than 1 case per 1000 patients. However, patients at high risk of helminthic infection should exercise caution, especially when traveling to regions where helminthic infections are endemic. If a patient does not respond to prescribed anti-helminthic treatment, discontinuation of Xolair should be considered.

Use during pregnancy or breastfeeding.

Moderate data from pregnant women (from 300 to 1,000 pregnancy outcomes) obtained from a pregnancy registry and spontaneous post-marketing reports indicate no teratogenic or fetal/neonatal toxicity. A prospective study from the pregnancy registry (EXPECT) involving 250 pregnant women with asthma who received Xolair showed that the prevalence of major congenital anomalies was similar (8.1% vs. 8.9%) in the EXPECT group and in patients with comparable conditions (moderate to severe asthma). Interpretation of these data may be limited by methodological constraints, including small sample size and non-randomized study design.

Omalizumab crosses the placental barrier; however, animal studies did not reveal any direct or indirect harmful effects on reproductive function. Omalizumab has been associated with age-related decreases in platelet counts in lower primates, with greater relative sensitivity in immature animals. Xolair treatment during pregnancy may be considered if clinically necessary.

Immunoglobulin G (IgG) is present in human breast milk; therefore, omalizumab is expected to be present in human breast milk. Omalizumab is excreted in breast milk of lower primates.

The EXPECT study, involving 154 infants exposed to Xolair in utero and during breastfeeding, found no adverse reactions in breastfed infants. Interpretation of these data may be limited by methodological constraints, including small sample size and non-randomized study design.

When administered orally, immunoglobulin G proteins undergo intestinal proteolysis and have low bioavailability. No impact on breastfed neonates/infants is expected. Therefore, Xolair treatment during breastfeeding may be considered if clinically necessary.

There are no data on the effect of omalizumab on human fertility. In specifically designed preclinical fertility studies, including mating studies, no impairment of male or female fertility was observed after repeated administration of omalizumab at doses up to 75 mg/kg. Furthermore, no genotoxic effects were observed in a separate preclinical genotoxicity study.

Ability to influence reaction speed when driving or operating machinery.

Xolair has no or negligible influence on the ability to drive a vehicle or operate machinery.

Method of administration and dosage.

Xolair should be prescribed by a physician experienced in the diagnosis and treatment of severe persistent asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

The same principles apply when determining the dosage for the treatment of allergic asthma and CRSwNP. The required dose and frequency of Xolair administration in these conditions are determined based on the IgE concentration (IU/mL) measured prior to initiating treatment, as well as the patient's body weight (kg). Prior to starting treatment, the patient's IgE level must be determined using a quantitative assay for total IgE with any commercially available serum test. Depending on these parameters, the recommended dose of Xolair ranges from 75 to 600 mg. This dose may be divided into 1 to 4 injections.

A lower likelihood of positive response has been observed in patients with allergic asthma whose IgE levels were below 76 IU/mL prior to starting treatment. Before initiating therapy, the physician should confirm in vitro reactivity (radioallergosorbent test [RAST]) to a perennial allergen in adult patients and children aged 12 years and older with IgE levels below 76 IU/mL, and in children aged 6 to 12 years with IgE levels below 200 IU/mL.

Dose calculations are provided in Table 5, and dose determination is outlined in Tables 6 and 7.

Xolair should not be prescribed to patients whose IgE levels or body weight exceed the values specified in the dosing table.

The maximum recommended dose is 600 mg of omalizumab every two weeks.

Table 5

Dose conversion into number of vials, number of injections, and total injection volume per administration

Dose (mg)	Number of vials		Number of injections	Total injection volume (ml)
	75 mg	150 mg
75	1	0	1	0.6
150	0	1	1	1.2
225	1	1	2	1.8
300	0	2	2	2.4
375	1	2	3	3.0
450	0	3	3	3.6
525	1	3	4	4.2
600	0	4	4	4.8

a 0.6 mL – maximum volume to be withdrawn from one vial (Xgeva, 75 mg);

b 1.2 mL – maximum volume to be withdrawn from one vial (Xgeva, 150 mg);

c or use of 0.6 mL from a 150 mg vial.

ADMINISTER EVERY 4 WEEKS.

Table 6

Doses of Xgeva (mg/dose) administered by subcutaneous injection every 4 weeks

Baseline IgE level (IU/mL)	Body weight (kg)
	>20–25*	>25–30*	>30–40	>40–50	>50–60	>60–70	>70–80	>80–90	>90–125	>125–150
≥30–100	75	75	75	150	150	150	150	150	300	300
>100–200	150	150	150	300	300	300	300	300	450	600
>200–300	150	150	225	300	300	450	450	450	600
>300–400	225	225	300	450	450	450	600	600
>400–500	225	300	450	450	600	600
>500–600	300	300	450	600	600
>600–700	300		450	600
>700–800
>800–900					ADMINISTER EVERY 2 WEEKS,
>900–1000						see TABLE 5
>1000–1100

* In the main studies for CRSwNP, body weight below 30 kg was not studied.

ADMINISTRATION EVERY 2 WEEKS.

Table 7

Doses of the medicinal product Xolair (mg/dose) administered by subcutaneous injection every 2 weeks

Baseline IgE (IU/mL)	Body weight (kg)
	>20–25*	>25–30*	>30–40	>40–50	>50–60	>60–70	>70–80	>80–90	>90–125	>125–150
≥ 30–100	ADMINISTER EVERY 4 WEEKS,
>100–200	see TABLE 4
>200–300										375
>300–400									450	525
>400–500							375	375	525	600
>500–600						375	450	450	600
>600–700		225			375	450	450	525
>700–800	225	225	300	375	450	450	525	600
>800–900	225	225	300	375	450	525	600
>900–1000	225	300	375	450	525	600
>1000–1100	225	300	375	450	600	Insufficient data to recommend a dose.
>1100–1200	300	300	450	525	600
>1200–1300	300	375	450	525
>1300–1500	300	375	525	600

* In the main studies for CRSwNP, body weight below 30 kg was not studied.

Administration. For subcutaneous use only. Do not administer intravenously or intramuscularly.

Doses exceeding 150 mg (Table 5) should be divided into two or more injections.

Experience with self-administration of Xolair as a powder for injection solution is limited. Therefore, the healthcare professional should administer the drug in this form.

Treatment duration, monitoring, and dose adjustment

Allergic asthma

Xolair is intended for long-term treatment. Clinical studies have confirmed the efficacy of Xolair treatment administered for at least 12–16 weeks. At week 16 after initiation of Xolair therapy, the patient's response to treatment should be evaluated prior to administering subsequent injections. The decision to continue Xolair therapy should be based on evidence of significant improvement in overall asthma control.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

In clinical studies, changes in nasal polyp score (NPS) and nasal congestion score (NCS) were observed within 4 weeks in CRSwNP. The need for continued therapy should be periodically reassessed based on the severity of the patient's disease and the level of symptom control.

Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)

Discontinuation of Xolair treatment in most cases leads to a rebound increase in free IgE levels and the development of corresponding symptoms. Total IgE levels remain elevated during treatment and stay elevated for up to one year after discontinuation of therapy. Therefore, repeated measurement of IgE levels during Xolair treatment cannot be used to determine the required dose of the drug. Dose determination after a treatment interruption lasting less than one year should be based on the IgE level obtained at initial dose determination. Serum total IgE levels may be re-measured for dose selection if Xolair treatment was interrupted for more than one year.

Dose adjustment is required with significant changes in body weight.

Chronic spontaneous urticaria, 150 mg dosing

The recommended dose is 300 mg administered as subcutaneous injections every 4 weeks.

The need for continued treatment should be periodically reassessed.

Clinical data on long-term treatment beyond 6 months for this indication are limited.

Special populations

Elderly (aged 65 years and older)

Limited data are available on the use of Xolair in patients over 65 years of age; however, there are no indications that a different dosing approach is required for elderly patients compared to younger adults.

Patients with renal or hepatic impairment

Studies on the effect of renal or hepatic impairment on the pharmacokinetics of Xolair have not been conducted. Since omalizumab clearance at clinical doses occurs primarily via the reticuloendothelial system (RES), changes due to renal or hepatic impairment are unlikely. Although there are no specific dose adjustment recommendations, Xolair should be used with caution in these patients.

Children

The safety and efficacy of Xolair for the treatment of allergic asthma in patients under 6 years of age have not been established. No data are available.

The safety and efficacy of Xolair for the treatment of CRSwNP in patients under 18 years of age have not been established.

Special instructions for use

The lyophilized product dissolves within 15–20 minutes, although in individual cases this process may take longer. The fully dissolved preparation will be colorless or light brown to yellow, clear or slightly opalescent, and may contain a few small air bubbles or foam on the vial walls. Because the solution is viscous, it is essential to completely withdraw the entire prepared solution—0.6 mL (for the Xolair 75 mg vial) or 1.2 mL (for the Xolair 150 mg vial)—before expelling air or excess solution from the syringe.

Xolair, powder for solution for injection, is supplied in single-use vials.

From a microbiological standpoint, the product should be used immediately after reconstitution.

Preparation and administration instructions for the solution.

1. For the Xolair 75 mg vial, draw 0.9 mL of water for injection from the ampoule into a syringe. For the Xolair 150 mg vial, draw 1.4 mL of water for injection from the ampoule into a syringe. The syringe needle should have a wide bore (gauge 18).
2. Place the vial upright on a flat surface, pierce the cap with the needle, and inject the water for injection into the vial containing the lyophilized powder, following standard aseptic procedures, directing the water directly onto the powder.
3. While holding the vial upright, rotate it vigorously (without shaking) for approximately 1 minute to evenly wet the powder.
4. To facilitate dissolution, gently rotate the vial for 5–10 seconds approximately every 5 minutes after step 3, until all remaining solid particles are dissolved.

Note that in some cases, complete dissolution of the powder may take more than 20 minutes. In such cases, repeat step 4 until visible gelatinous particles in the solution disappear.

Once fully dissolved, the solution should not contain visible gelatinous particles. Fine bubbles or foam around the edge of the vial are usually present. The reconstituted preparation should appear clear or opalescent. Do not use if gelatinous particles are present.

1. Invert the vial for at least 15 seconds to allow the solution to flow toward the stopper. Using a 3 mL syringe equipped with a wide-bore 18-gauge needle, insert the needle into the inverted vial. While holding the vial inverted (the needle tip should be near the vial cap in the solution), draw the solution into the syringe. Before removing the needle from the vial, pull the plunger back fully to withdraw all solution from the inverted vial.
2. Replace the 18-gauge needle with a 25-gauge needle for subcutaneous injection.
3. Expel air, large bubbles, and any excess solution to achieve the required dose (0.6 or 1.2 mL). A thin layer of fine bubbles may remain on the solution surface in the syringe. Because the solution is slightly viscous, it may take 5–10 seconds to administer the subcutaneous injection.

Each vial contains 0.6 mL (75 mg) or 1.2 mL (150 mg) of Xolair.

1. Administer the injection subcutaneously into the deltoid area of the upper arm or the thigh.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Children.

Xolair is not recommended for use in children under 6 years of age due to insufficient safety and efficacy data.

Overdose.

The maximum tolerated dose of Xolair has not been determined. Intravenous administration of single doses up to 4,000 mg in patients did not result in dose-limiting toxicity. The highest cumulative dose administered to a patient was 44,000 mg over a 20-week period and did not cause any acute adverse effects.

In case of suspected overdose, monitor the patient for any unusual symptoms. Appropriate diagnosis should be established and treatment administered accordingly.

Adverse reactions.

Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)

During clinical trials in adults and children aged 12 years and older with allergic asthma, the most common adverse reactions were headache and injection site reactions, including pain, swelling, erythema, and pruritus at the injection site. In clinical trials in children aged 6 to 12 years, the most common drug-related adverse reactions were headache, pyrexia, and upper abdominal pain. Most reactions were of mild or moderate severity. In clinical trials in patients aged 18 years and older with CRSwNP, the most common drug-related adverse reactions were headache, dizziness, arthralgia, upper abdominal pain, and injection site reactions.

In Table 8, adverse reactions observed during clinical trials in the overall safety study population in allergic asthma and CRSwNP are listed by MedDRA System Organ Class and frequency. Within each frequency group, adverse reactions are presented in descending order of severity. Frequency is defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), and very rare (<1/10,000). The frequency of events reported during the post-marketing period, for which the frequency cannot be estimated based on available data, is listed as unknown.

Table 8

Frequency	Adverse Reactions
Infections and infestations
Uncommon	Pharyngitis
Rare	Parasitic infestations
Blood and lymphatic system disorders
Frequency unknown	Idiopathic thrombocytopenia, including severe cases
Immune system disorders
Rare	Anaphylactic reaction, other serious allergic conditions, development of antibodies to the drug
Frequency unknown	Serum sickness, which may include fever and lymphadenopathy
Nervous system disorders
Common	Headache*
Uncommon	Syncope, paraesthesia, somnolence, dizziness***
Vascular disorders
Uncommon	Postural hypotension, flushing
Respiratory, thoracic and mediastinal disorders
Uncommon	Allergic bronchospasm, cough
Rare	Laryngeal edema
Frequency unknown	Allergic granulomatous vasculitis (Churg–Strauss syndrome)
Gastrointestinal disorders
Common	Upper abdominal pain**,***
Uncommon	Signs or symptoms of dyspepsia, diarrhea, nausea
Skin and subcutaneous tissue disorders
Uncommon	Photosensitivity, urticaria, rash, pruritus
Rare	Angioneurotic edema
Frequency unknown	Alopecia
Musculoskeletal and connective tissue disorders
Uncommon Rare Frequency unknown	Arthralgia**** Systemic lupus erythematosus (SLE) Myalgia, joint swelling
General disorders and administration site conditions
Very common	Pyrexia**
Common	Injection site reactions such as swelling, erythema, pain, pruritus
Uncommon	Influenza-like illness, swelling of extremities, weight increase, fatigue

* Very common in children aged 6 to 12 years.

** In children aged 6 to 12 years.

*** Common in studies on nasal polyps.

**** Frequency unknown in studies on allergic asthma.

Chronic spontaneous urticaria

The safety and tolerability of omalizumab were evaluated in 975 patients with CSU who received doses of 75 mg, 150 mg, and 300 mg every 4 weeks, of whom 242 received placebo. Overall, 733 patients received omalizumab for up to 12 weeks and 490 patients for up to 24 weeks. Of these, 412 patients received omalizumab for up to 12 weeks and 333 patients received omalizumab for up to 24 weeks at a dose of 300 mg.

As shown in Table 9, adverse reactions in CSU occurred across different dose groups and in patients with various confirmed risk factors, concomitant diseases, age groups, and concomitantly used medicinal products (e.g., asthma studies included children aged 6 to 12 years).

Table 9 lists adverse reactions (events occurring in ≥1% of patients in any treatment group and occurring ≥2% more frequently in any omalizumab treatment group compared to placebo [after medical evaluation]) observed with the 300 mg dose in three pooled Phase III studies. The listed adverse reactions are divided into two groups: those occurring during the 12-week and 24-week treatment periods.

Adverse reactions are listed by MedDRA system organ class. Within each organ system class, adverse reactions are listed in descending order of frequency. Frequency categories are defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (frequency cannot be estimated from the available data).

Table 9
Adverse reactions from pooled safety databases in CSU (Day 1 – Week 24) during omalizumab treatment at a dose of 300 mg
12-week treatment	Pooled Studies 1, 2, and 3 of omalizumab		Frequency category
	Placebo N=242	300 mg N=412
Infections and infestations
Sinusitis	5 (2.1%)	20 (4.9%)	Common
Nervous system disorders
Headache	7 (2.9%)	25 (6.1%)	Common
Musculoskeletal and connective tissue disorders
Arthralgia	1 (0.4%)	12 (2.9%)	Common
General disorders and administration site conditions
Injection site reactions*	2 (0.8%)	11 (2.7%)	Common
24-week treatment	Pooled Studies 1 and 3 of omalizumab		Frequency category
	Placebo N=163	300 mg N=333
Infections and infestations
Upper respiratory tract infection	5 (3.1%)	19 (5.7%)	Common

* Although a greater than 2% difference compared to placebo was not observed, injection site reactions were included because a causal relationship to treatment within the study was established in all cases.

Description of individual adverse reactions related to allergic asthma and CRSwNP

Immune system disorders

For additional information, see section "Special precautions for use".

Anaphylaxis

Anaphylactic reactions during clinical trials were very rare. However, based on a comprehensive search of the post-marketing safety database, a total of 898 cases of anaphylaxis have been reported. Based on an estimated exposure of 566,923 patient-years of treatment, the reporting rate is 0.20%.

Arterial thromboembolism (ATE)

Numerical imbalance in ATE events was observed in controlled clinical trials and ongoing observational studies. ATE included stroke, transient ischemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause). In the final analysis of the observational study, the rate of ATE per 1,000 patients was 7.52 (115/15,286 patient-years) in patients receiving Xolair and 5.12 (51/9,963 patient-years) in the control group. In a multivariate analysis adjusted for baseline cardiovascular risk factors, the risk ratio was 1.32 (95% confidence interval 0.91–1.91). In a separate analysis of pooled clinical trials, which included all randomized, double-blind, placebo-controlled clinical trials of 8 weeks or longer duration, the rate of ATE per 1,000 patient-years was 2.69 (5/1,856 patient-years) in patients receiving Xolair and 2.38 (4/1,680 patient-years) in the placebo group (risk ratio 1.13, 95% confidence interval 0.24–5.71).

Platelets

During clinical trials, several patients had platelet counts below the lower limit of the normal laboratory reference range. In none of these cases did this change lead to bleeding episodes or a decrease in hemoglobin levels. Cases of persistent thrombocytopenia, as observed in non-human primates, were not observed in humans (patients aged 6 years and older), although isolated reports of idiopathic thrombocytopenia, including severe cases, were received during post-marketing surveillance.

Parasitic infections

A placebo-controlled study showed a slight increase in the incidence of parasitic infections in patients with ongoing high risk of helminth infestation during omalizumab treatment, which was not statistically significant. The course, severity, and response to treatment of these infestations were unchanged.

Shelf life. 4 years.

Chemical and physical stability of the reconstituted medicinal product has been demonstrated for 8 hours at 2–8 °C and for 4 hours at 30 °C.

From a microbiological standpoint, the medicinal product should be used immediately after reconstitution.

If not used immediately, the user is responsible for the duration and conditions of storage, which should generally not exceed 8 hours at 2–8 °C or 2 hours at 25 °C.

Storage conditions.

Store at 2–8 °C in a place inaccessible to children. Do not freeze.

Incompatibilities.

Xolair may only be reconstituted with water for injection.

Packaging.

A clear glass vial containing a stopper made of butyl rubber and a blue (150 mg) or grey (75 mg) cap.

Water for injection in clear, colorless glass ampoules of 2 ml.

The pack contains one vial of powder and one ampoule of water for injection.

Prescription status. Prescription only.

Manufacturer.

for 75 mg

Novartis Pharma Stein AG, Switzerland / Novartis Pharma Stein AG, Switzerland.

for 150 mg

Novartis Pharma Stein AG, Switzerland / Novartis Pharma Stein AG, Switzerland.

or

Lek Pharmaceuticals d.d., Slovenia / Lek Pharmaceuticals d.d., Slovenia

Manufacturer's address and location of operations.

for 75 mg

Schaffhauserstrasse, 4332 Stein, Switzerland / Schaffhauserstrasse, 4332 Stein, Switzerland.

for 150 mg

Schaffhauserstrasse, 4332 Stein, Switzerland / Schaffhauserstrasse, 4332 Stein, Switzerland.

or

Verovskova Ulica 57, Ljubljana, 1526, Slovenia / Verovskova Ulica 57, Ljubljana, 1526, Slovenia.